Updated: Wed, 10/09/2024 - 15:16

Oct. 10-11, campus is open to McGill students, employees and essential visitors. Most classes are in-person. See Campus Public Safety website for details.


Les 10 et 11 octobre, le campus est accessible aux étudiants et au personnel de l’Université, ainsi qu’aux visiteurs essentiels. La plupart des cours ont lieu en présentiel. Voir le site Web de la Direction de la protection et de la prévention pour plus de détails.

News

News | Pleins feux sur la technologie ARN | La Presse

Person in a lab wearing blue gloves holding a test tube.
Image by Charles William Pelletier, Collaboration Speciale.
Published: 13 September 2024

A recent article in La Presse, Pleins feux sur la technologie ARN, highlights how Quebec's life sciences sector is experiencing a significant revival with the creation of an RNA hub.

Here is a exerpt from the article (translated to english): 

“There's an incredible amount of excitement.” That's how Claude LeDuc, CEO of RNA Technologies & Therapeutics (RNA T & T), sums up the climate in Montreal's life sciences and health technology sector.

His company, which specializes in the design, optimization and small- to medium-scale production of RNA, as well as the development of messenger RNA (mRNA)-based therapeutics, has had a flawless track record since its launch in July 2022.

It's extraordinary,” admits Claude LeDuc. Within a month of our existence, we had found a laboratory in Laval and started our RNA commercialization activities. Within the first few months, we had generated enough funds to be financially self-sufficient.”

Without giving any figures, he adds that the 10-employee company raked in “significant surpluses” in its first financial year. “That enabled us to buy $1 million worth of equipment, with the support of government programs. We managed to quintuple the capacity of certain stages of our production. We're still growing. We want to become a center of RNA production for personalized medicine.”

In June, RNA T & T moved its headquarters to the Institut de recherches cliniques de Montréal (IRCM). The company is currently working on three research projects with the IRCM, to test the efficacy of innovative approaches to treating leukemia, cancer and diabetes.

Frank Béraud, President and CEO of Montréal InVivo, notes that Québec - and Montréal in particular - has “very strong expertise” in RNA. “It's a niche of excellence that's developing,” he says. The launch of AReNa, the province's RNA hub, has mobilized players in the sector. The first projects selected for funding will be unveiled in the coming days.

Claude LeDuc believes that the investments announced, including the $20 million over two years to make Quebec an innovation hub, will “accelerate the development of RNA therapies”.

Click here to read the full article. 

Back to top